Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai

publication date: Jan 19, 2018

Adlai Nortye Biopharma of Hangzhou acquired global rights to a novel immuno-oncology oral EP4 antagonist developed by Japan's Eisai Co. Eisai has reported positive results from a Phase I test of the drug in Japan, where it will retain rights. Adlai Nortye will have exclusive worldwide research, development, manufacturing and commercialization rights to E7046, excluding Japan and some other Asian countries, though it will have rights for Mainland China. Financial details of the agreement were not disclosed. More details....

Stock Symbol: (NEEQ: 870946)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.